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Abstract
Colorectal cancer (CRC) is a significant health problem, 
with around 1 million new cases and 500000 deaths 
every year worldwide. Over the last two decades, the 
use of novel therapies and more complex treatment 
strategies have contributed to progressively increase 
the median survival of patients with unresectable ad-
vanced CRC up to approximately 30 mo. The availability 
of additional therapeutic options, however, has created 
new challenges and generated more complicated treat-
ment algorithms. Moreover, several clinically important 
points are still in debate in first-line, such as the optimal 
treatment intensity, the most appropriate maintenance 
strategy, the preferred biologic to be used upfront in 
patients with KRAS wild-type CRC, and the need for 
more detailed information on tumor biology. In this 
moving landscape, this review analyses why the first-
line treatment decision is crucial and how the choice 
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may impact on further treatment lines. In addition, it 
focuses on results of major phase Ⅲ randomized trials.
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Core tip: The choice of the first-line therapy is crucial 
for patients with advanced, unresectable colorectal 
cancer. The aim of this review is to critically focus on 
updated scientific data that medical oncologists need to 
interpret to make the most appropriate evidence-based 
choice among many possible treatment options.
Aprile G, Lutrino SE, Ferrari L, Casagrande M, Bonotto M, On-
garo E, Puglisi F. Evidence-based appraisal of the upfront treat-
ment for unresectable metastatic colorectal cancer patients. World 
J Gastroenterol 2013; 19(46): 8474-8488  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v19/i46/8474.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v19.i46.8474
WHICH REASONING DOES LIE 
BENEATH THE CHOICE OF A FIRST-LINE 
TREATMENT?
Colorectal cancer (CRC) is currently the second most 
common cancer in Europe, with nearly 450000 new cases 
and approximately 215000 deaths occurred in 2012[1]. 
Half  of  those patients are either initially diagnosed at 
an advanced or metastatic stage or later develop distant 
metastases, and have a 5-year survival rate of  5%-10%[2]. 
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metastases has been reported to increase the chance of  
cure in selected patients, palliative systemic treatments 
may at least produce survival benefits for those present-
ing with diffuse unresectable disease. Over the last two 
decades, the median survival of  patients with metastatic 
CRC has progressively improved, approaching 30 mo in 
recent reports. Notably, not only the widespread use of  
all available active agents (including 4 different chemo-
therapy drugs and 5 biologics) has shaped this clinical 
success, but also more patients have profited enhanced 
quality of  life while receiving modified or less intensive 
maintenance treatments or while enjoying chemotherapy-
free intervals. In fact, a smoother, more plastic concept 
embracing a “comprehensive treatment strategy” has 
substituted the rigid classical sequence of  following 
structured treatment lines in the continuum of  care. Not-
withstanding those significant advances, the treatment 
landscape for unresectable advanced CRC has become 
increasingly complex. For all those incurable patients, 
mainstay of  the treatment is to maximise survival while 
minimizing toxicities and maintaining optimal quality of  
life. The availability of  more therapeutic options, how-
ever, has generated intricate algorithms of  treatment 
decision-making and medical oncologists are often over-
whelmed by a large number of  trials providing unclear or 
conflicting results. 
Unquestionably, when deciding the delivery of  an 
optimally personalized treatment sequence, the ultimate 
treatment goal, outcome data from randomized clinical 
trials, different regimen-related toxicity profiles, molecular 
status of  the disease, and patients’ willingness should all 
be considered. However, while recent guidelines suggest 
to combine chemotherapy with targeted agents for the 
vast majority of  those aged less than 75 years[3], it is much 
less clear which patients deserve a higher treatment inten-
sity and which is the best biologic to use upfront for CRC 
patients with KRAS wild-type disease[4]. Moreover, it 
should be acknowledged that the proportion of  patients 
receiving therapy diminishes with subsequent lines and 
that efficacy results are the greatest in untreated patients 
and usually reduce along with treatment course because 
of  a growing degree of  chemoresistance. The foundation 
of  the upfront treatment is, therefore, crucial: in first-
line setting the highest number of  patients may benefit 
therapies with the highest response rates and the longest 
median progression-free survival (PFS). Moreover, there 
is still a chance for unexpected resection and even cure, 
and for all those who will not be cured, first-line therapy 
may impact on overall survival (OS). 
Actually, whenever discussing with a previously un-
treated patient the different first-line treatment options, 
some clinical considerations should be made: (1) How 
long will the patient survive and how long will the patient 
benefit from first-line treatment? (2) Does the patient 
need (and agree on) an aggressive strategy? (3) Will a 
deeper knowledge of  tumor molecular biology aid in 
the decision-making process? (4) May the patient benefit 
from maintaining an antiangiogenic strategy across treat-
ment lines? and (5) Has the first-line choice potential im-
pact on further treatment lines?
In addition, if  the patients has previously received 
adjuvant chemotherapy (indeed, approximately 30% of  
metastatic CRC patients had), other questions arise: (1) 
How long have the patient lived without evidence of  
disease? (in other words, how long did the disease-free 
interval last?) and (2) May previous adjuvant treatments 
condition the first-line treatment choice?
Reporting as a springboard for discussion results 
from key randomized clinical trials (Table 1), aim of  this 
viewpoint is to help clinicians making an evidence-based 
decision when choosing among possible first-line treat-
ments for their medically-fit advanced unresectable CRC 
patients.
WHEN TO TREAT PATIENTS WITH 
HIGHER INTENSITY? SEARCHING FOR 
THE OPTIMAL FINE-TUNING
The idea of  combining all available drugs upfront with 
the aim to hit and immediately kill as many cancer cells as 
possible is certainly not new. In CRC, the combination of  
5-fluorouracil, oxaliplatin, and irinotecan (FOLFOXIRI) 
was initially compared to 5-fluorouracil and irinotecan 
(FOLFIRI) in two independent studies[5,6]. Results from 
the phase Ⅲ randomized Italian trial showed significant 
advantage for the triplet in terms of  RR (66% vs 41%, P 
= 0.0002), PFS (9.8 mo vs 6.9 mo, HR = 0.63), OS (22.6 
mo vs 16.7 mo, HR = 0.70), and secondary resections for 
those with liver-limited disease (36% vs 12%, P = 0.01), 
thus presenting such an intensive upfront regimen among 
the potential choices to be used when a significant tumor 
shrinkage is needed. Oppositely, although based on an 
encouraging preclinical[7] and clinical[8] background, final 
results of  combining doublet chemotherapy with both 
bevacizumab and Epidermal Growth Factor Receptor 
(EGFR)-inhibitors were vastly disappointing[9,10]. Overall, 
both the randomized phase Ⅲ CAIRO2 and PACCE 
studies showed significantly reduced PFS outcome results 
and increased toxicity profiles for the 4-drugs combina-
tion when compared to chemotherapy plus bevacizu-
mab alone. The reasons for the unforeseen antagonism 
between the two biologic agents when combined with 
chemotherapy are still uncertain[11]. The issue regarding 
how much intense the chemotherapy backbone should 
be remains critical also in the era of  targeted agents. Two 
randomized trials, phase Ⅲ TRIBE[12] and phase Ⅱ OL-
IVIA[13], investigated the combination of  the FOLFOX-
IRI based-regimen with the antiangiogenic bevacizumab. 
In the first trial, 508 advanced CRC patients received 
upfront FOLFIRI or FOLFOXIRI plus bevacizumab. 
Patients in the experimental arm achieved a significantly 
longer PFS (12.1 mo vs 9.7 mo; HR = 0.77, 95%CI: 
0.64-0.93, P = 0.006). The triplet also provided a signifi-
cant increase in RR (65% vs 53%, P = 0.006), but not in 
radical resection rate (15% vs 12%, P = 0.327). Neverthe-
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less, the study population was unselected for conversion 
to surgical resectability, since only 20% of  randomized 
patients had liver-limited disease. Preliminary data 
showed a trend toward improved OS in the FOLFOX-
IRI plus bevacizumab arm (31.0 mo vs 25.8 mo; HR = 
0.83, 95%CI: 0.66-1.05). Phase Ⅱ OLIVIA trial allocated 
80 advanced CRC patients with liver-only unresectable 
metastases to receive 5-fluorouracil and oxaliplatin (FOL-
FOX) or FOLFOXIRI plus bevacizumab. Overall resec-
tion rate, the primary endpoint, was numerically higher 
in the FOLFOXIRI plus bevacizumab arm (61.0% vs 
48.7%, P = 0.27). The more intensive regimen provided 
both a higher RR (80.5% vs 61.5%, P = 0.061) and radi-
cal (R0) resection rate (48.8% vs 23.1%, P = 0.017), with 
longer PFS (18.8 mo vs 12.0 mo, P = 0.0002). Moreover, 
retrospective data suggest that the addition of  bevacizu-
mab to the FOLFOXIRI regimen does not impact on 
liver toxicity while enhancing the rate of  pathologic re-
sponse and tumor necrosis[14].
The combination of  FOLFOXIRI with EGFR-in-
hibitors showed also interesting results in a phase Ⅱ trial, 
but a formal phase Ⅲ comparison of  the added benefit 
of  cetuximab or panitumumab to the triplet regimen is 
currently lacking. In the TRIP study, 37 highly molecu-
larly selected patients (concomitant wild-type status for 
KRAS, BRAF, NRAS, and HRAS) received FOLFOXIRI 
plus panitumumab with a reported RR of  89%. Forty-
three percent of  them underwent secondary surgery of  
metastases, and R0 resection was achieved in 13 cases 
(35%). After a median follow-up of  17.7 mo, median PFS 
was 11.3 mo[15]. Another phase Ⅱ study enrolled 43 CRC 
patients with unresectable liver metastases to receive ce-
tuximab plus chronomodulated irinotecan, 5-fluorouracil, 
leucovorin and oxaliplatin as neoadjuvant chemothera-
py[16]. After a median number of  6 cycles, RR was noted 
in 79% of  patients, and median OS was of  37 mo.
Based on available results, when should we opt for a 
very intensive treatment? The use of  triplet plus bevaci-
zumab could be considered a possible treatment option 
for those who parallel the trial’s inclusion criteria (i.e., 
unresectable, metastatic disease, age < 75 years; optimal 
ECOG PS, no major comorbidities), but this appears 
to be a much more intriguing and logical option for pa-
tients with symptomatic, bulky or aggressive disease or 
when conversion from unresectable to resectable status is 
deemed possible (liver-limited unresectable metastases). 
In the first circumstance, patients may benefit from a fast 
disease shrinkage that while reducing the tumor burden 
may better control cancer-related symptoms or avoid 
their occurrence. In the second condition, the advantage 
of  using this highly active combination is that it may ex-
ert its effect in few cycles, avoiding a sustained exposure 
to chemotherapy that might potentially increase liver 
toxicity just before hepatic surgery. Although phase Ⅱ 
studies results are promising, the use of  a triplet regimen 
combined with EGFR-inhibitors outside of  a clinical trial 
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Table 1  Outcome results of major randomized phase Ⅲ trials in the first-line setting in metastatic colorectal cancer patients
Ref.                Regimen n Previous adjuvant 
treatment




IFL 411 28%    34.8%     6.2    15.6 50%
Hurwitz et al[80] IFL+bevacizumab 402 24%    44.8%   10.6    20.3 50%
Cunningham et al[118] Capecitabine 140    18.6% 10%     5.1    16.8 37%
Capecitabine + bevacizumab 140    32.1% 19%     9.1    20.7 37%
Saltz et al[8] XELOX/FOLFOX 701  25%1 38%   8    19.9 53%
XELOX/FOLFOX + bevacizumab 699  24%1 38%      9.4    21.3 46%
Heinemann et al[81] FOLFIRI + cetuximab 297    22.1% 62% 10    28.7    65.7%
FOLFIRI + bevacizumab 295    18.9% 58%    10.3 25    61.7%
Capecitabine 156 22%    30.3%      5.7    18.9 68%
Tebbutt et al[119] Capecitabine + bevacizumab 157 28%    38.1%      8.5    18.9 62%
Capecitabine + bevacizumab + MMC 158 16%    45.9%      8.4    16.4 61%
Falcone et al[12] FOLFOXIRI + bevacizumab 252 12% 65% 12 31 NA3
FOLFIRI + bevacizumab 256 12% 53%      9.7    25.8 NA3
Van Cutsem et al[82] FOLFIRI 599    18.9%    39.7%      8.4 20    71.7%
FOLFIRI + cetuximab 599    17.4%    57.3%      9.9    23.5 66%
Maughan et al[91] XELOX/FOLFOX2 815  25%1 57%      8.6 17 62%
XELOX/FOLFOX + cetuximab 815  25%1 64%      8.6    17.9 56%
Tveit et al[120] FLOX 185    8%1 41%      7.9    20.4    73.5%
FLOX + cetuximab 194    9%1 49%      8.3    19.7    75.8%
FLOX intermittently + cetuximab 187  10%1 47%      7.3    20.3    64.2%
Douillard et al[90] FOLFOX4 590  15%1 48%   8    19.7 63%
FOLFOX4 + panitumumab 593     16.1%1 55%      9.6    23.9 53%
Schmoll et al[89] FOLFOX + bevacizumab 713 19%    47.3%    10.3    21.3    23.8%
FOLFOX + cediranib 709 17%    46.3%      9.9    22.8    28.2%
Díaz-Rubio et al[60] XELOX + bevacizumab 239  13%1 47%    10.4    23.2 72%
XELOX + bevacizumab→bevacizumab 241  17%1 49%      9.7 20 74%
1No previous oxaliplatin-based treatment allowed; 2Both Arm A (continuously) and Arm B (intermittently) have been considered; 3Data will be available in 
2014. ORR: Overall response rate; PFS: Progression-free survival; OS: Overall survival; IFL: Irinotecan, fluorouracil, leucovorin therapy; FOLFIRI: 5-fluoro-
uracil and irinotecan; XELOX: Capecitabine/oxaliplatin.
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in PFS were documented (HR = 1.06; 95%CI: 0.88-1.26, 
P = 0.54). Of  note, in the cohort of  patients assessable 
for response (n = 526, 89%), encompassing all those who 
had received a minimum of  3 cycles and had performed 
at least a CT-scan evaluation following baseline, RR was 
significantly higher in favour of  cetuximab-containing 
arm (72.2% vs 63.1%, OR = 1.52, P = 0.017). Although, 
no significant differences in median PFS were reported 
(10 mo vs 10.3 mo, HR = 1.03; 95%CI: 0.88-1.26), a clini-
cally meaningful 3.7-month median advantage in OS was 
evidenced in favour of  the cetuximab arm (28.7 mo vs 
25 mo, HR = 0.77; 95%CI: 0.62-0.96), confirmed in all 
exploratory subgroups analysed. Disparities in subse-
quent treatment lines may hardly explain this unforeseen 
survival difference, being the proportion of  patients who 
crossed over or received treatment beyond progression 
similar between treatment arms (65.7% in the cetuximab 
arm vs 61.7% in the bevacizumab arm, P = 0.34). Op-
positely, the association of  both early tumor shrinkage 
(at least 20% decrease in the sum of  the longest diameter 
compared with baseline at week 8) and the deepness of  
response (percentage of  tumor shrinkage observed at 
the smallest tumor size compared to baseline) to EGFR-
inhibitors with the post-progression survival were ad-
vocated as possible reasons for success[32]. According to 
this theoretical model, the higher tumour shrinkage may 
result in a lower tumour load, as per RECIST, at the time 
of  disease progression so that the benefit achieved in 
terms of  deepness of  response may influence the fol-
lowing history of  patients’ disease. Likewise, a significant 
correlation of  the early objective tumor response (EOTR) 
with survival was demonstrated by an individual patient 
data meta-analysis of  15 randomized first-line trials en-
rolling approximately 12000 patients from the ARCAD 
database[33]. In the analysis, median PFS and median OS 
were consistently longer in patients with an EOTR at 6, 
8 or 12 wk compared to those without. Overall, these re-
sults support the hypothesis that the advantage in terms 
of  activity of  an intensive upfront regimen may translate 
into a significant survival gain regardless the opportunity 
to achieve secondary resections. While a confirmatory 
correlation analysis is being conducted in FIRE-3 trial, 
outcome results from a larger intergroup phase Ⅲ trial 
(CALGB 80405, NCT00265850) that aims to compare 
upfront chemotherapy with bevacizumab or cetuximab 
in over 1200 metastatic CRC patients are awaited. Differ-
ently from FIRE-3, OS is the primary endpoint of  the 
CALGB and SWOG cooperative groups trial.
To simultaneously explore the head-to-head compari-
son and the treatment strategy, the GERCOR is sponsor-
ing the phase Ⅲ STRATEGIC-1 trial[34] that is designed 
to provide information on the optimal treatment se-
quence, with two different strategies each including all 
the currently available agents (oxaliplatin, irinotecan, fluo-
ropyrimidines, bevacizumab, and EGFR-inhibitors), but 
in a different order. With disease control rate of  the full 
strategy as the primary endpoint, nearly 500 patients with 
unresectable wild-type KRAS metastatic CRC will be 
should be currently discouraged, even in patients with 
optimal molecular selection. In order to ameliorate the 
tolerability, the intensification of  the upfront therapy in 
never resectable patients usually requires to plan a short 
initial treatment period (induction phase) followed by a 
less intensive treatment (maintenance phase). To avoid 
excessive toxicity in a palliative setting, the strength of  
such an induction treatment should last no longer than 8 
cycles. After that, patients are usually switched to an ap-
propriate, more tolerable, maintenance regimen that may 
be continued for a long period. Ongoing studies are clari-
fying the role of  the maintenance therapy and expound-
ing which are the optimal agents to be used. Potential 
drawbacks of  an intensive treatment include higher toxic-
ity and more limited rescue options once the tumor has 
become resistant.
WHICH BIOLOGIC SHOULD BE 
PREFERRED IN THE UPFRONT 
TREATMENT OF KRAS WILD-TYPE CRC 
PATIENTS?
Although the predictive role of  G13D mutation still re-
mains a matter of  discussion[17-19], having a KRAS muta-
tion in codon 12 or 13 is a universally accepted marker 
for EGFR-inhibitor inefficacy[20,21]. Other germline 
mutations in RAS or BRAF genes also seem to predict 
unfavourable results[22,23], and acquired secondary mu-
tations may cause resistance to EGFR-inhibitors[24-26]. 
Moreover, retrospective data confirmed that using a 
more adequate technique RAS or BRAF mutations were 
found in approximately 20% of  cancers initially classified 
as wild-type[20], and this might help in refining the target 
population[27,28]. Current molecular selection has a nega-
tive predictive value, but it does not help in the clinical-
decision process for patients with wild-type CRC. Actu-
ally, which targeted agent should be combined to first-line 
chemotherapy in KRAS wild-type patients is one of  the 
hot-topics in colorectal oncology. Up today, the choice 
was essentially based on cross-trial comparisons and on 
meta-analyses estimating the magnitude of  benefit pro-
vided by each targeted agent[29,30]. While EGFR-inhibitors 
were considered powerful shrinking agents, bevacizumab 
was preferred for its ability to delay tumor progression. 
FIRE-3, the first phase Ⅲ randomized trial to provide 
results on the head-to-head comparison, randomized 592 
KRAS wild-type CRC patients to upfront FOLFIRI plus 
either cetuximab or bevacizumab, with the aim to detect 
a difference of  12% in RR induced by FOLFIRI plus ce-
tuximab (62%) compared to FOLFIRI plus bevacizumab 
(50%)[31]. Though unusual for a randomized phase Ⅲ tri-
al, RR was chosen as the primary endpoint of  the study. 
Because of  a higher than expected treatment activity re-
ported for patients exposed to bevacizumab, RR resulted 
similar between treatment arms (62% in the FOLFIRI 
plus cetuximab arm vs 58% in the FOLFIRI plus beva-
cizumab arm, OR = 1.18, P = 0.18) and no differences 
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randomized to FOLFIRI-cetuximab, followed by an ox-
aliplatin-based chemotherapy with bevacizumab (Strategy 
A) or OPTIMOX-bevacizumab, followed by irinotecan-
based chemotherapy with bevacizumab, followed by an 
EGFR-inhibitor with or without irinotecan (Strategy B). 
The study is starting soon the target recruitment.
TOWARD A BETTER MOLECULAR 
SELECTION? BROADENING CRC 
BIOLOGIC KNOWLEDGE BEYOND KRAS
Since the acknowledgment that CRC is a highly hetero-
geneous disease with regards to clinical evolution and 
response to treatments and the fact that it may change 
over time or evolve under treatment pressure[35], a more 
profound molecular knowledge of  this cancer has been 
promoted[36]. Actually, a deeper understanding of  the 
disease pathobiology and its molecular underpinnings 
allow clinicians to take advantage of  a more detailed 
disease classification[37] and more robust information on 
predictive and prognostic biomarkers as well as resist-
ance bioindicators for both antiangiogenic[38] and EGFR-
inhibitors[39]. Whether serial tumor biopsies and repeated 
mutation testing may be useful to better capture the CRC 
heterogeneity and to systemically track its genomic evo-
lution is a matter of  debate[40,41], but the application of  
innovative, low-invasive techniques may find acceptance 
from both scientific and ethical standpoints[42,43]. Specifi-
cally focusing on the treatment tailoring, the landscape 
has rapidly evolved beyond KRAS codon 12 and 13 mu-
tational status[44]. For example, rare mutation occurring in 
other KRAS codons, such as mutation in codons 61 or 
146, may result in reduced EGFR-inhibitor efficacy[22]. As 
well, V600E BRAF mutations occurring in approximately 
10% of  all KRAS wild-type CRC tumors[45] or more rare 
KRAS amplifications[46] seem to limit the benefit from 
EGFR-inhibitors[47-49]. However, while there is total agree-
ment on its negative prognostic value, the negative pre-
dictive role of  BRAF mutations with regards to EGFR-
inhibitor therapy is not universally accepted[50-52] and 
loss of  PTEN expression or activity[53,54] have also been 
associated to inferior benefit from EGFR-inhibitors, but 
the small sample size of  the cohort analysed linked to 
the relatively rare events prevent to draw strong definitive 
conclusions.
Importantly, the use of  EGFR-inhibitors in the clini-
cal practice should be based on a deep molecular analysis 
with further refinement of  tumor-specific genetic mark-
ers in order to simultaneously allow: (1) identification of  
a wider patient population that does not benefit from 
the target treatment or may have detrimental effect; and 
(2) selection of  patients who may achieve a maximized 
survival improvement. A prospective-retrospective 
analyses of  phase Ⅲ PRIME trial[55] that randomized 
1083 patients to upfront FOLFOX plus or minus pani-
tumumaband a preplanned analysis of  phase Ⅱ PEAK 
study that assigned in first-line 285 patients to FOLFOX 
plus either bevacizumab or panitumumab[56] consistently 
show that patients harbouring rare KRAS mutations 
in exon 3 (codons 59/61) and 4 (codons 117/146), or 
NRAS mutations in exon 2 (codons 12/13), 3 (codons 
59/61), and 4 (codons 117/146) may not benefit from 
the EGFR-inhibitor. In the first analysis, patients with-
out RAS mutations had a 2.2 mo median advantage in 
median PFS (10.1 mo vs 7.9 mo, HR = 0.72, 95%CI: 
0.58-0.9, P = 0.004), and a 5.8 median advantage in OS (26 
mo vs 20.2 mo, HR = 0.78, 95%CI: 0.62-0.99, P = 0.04). 
Impressively, patients with no RAS or BRAF mutations 
(n = 446) derived a 7.6 median survival benefit (28.3 mo 
vs 20.9 mo, HR = 0.74, 95%CI: 0.57-0.96, P = 0.02) if  
exposed to FOLFOX and panitumumab in first-line. An 
exploratory biomarker tumor analysis[57] of  patients en-
rolled in the panitumumab vs BSC randomized phase Ⅲ 
study[58] reported similar results. Importantly, the addition 
of  panitumumab to first-line FOLFOX might be even 
detrimental in patients with less common RAS mutations 
and should be cautiously avoided. On the basis of  these 
data, marketing authorization for panitumumab has been 
amended, including the analysis of  NRAS status before 
prescription, and restraining its use to RAS wild-type 
CRC patients. Since it has been highlighted how a more 
detailed molecular profile may impact on the evidence-
based decision making process, a more accurate selection 
of  candidates to upfront EGFR-inhibitors is warranted. 
Results of  a similar deeper molecular analysis in patients 
exposed to upfront cetuximab or bevacizumab combined 
with FOLFIRI in the FIRE-3 trial will be soon presented.
ANGIOGENIC INHIBITORS UPFRONT AND 
IN THE FOLLOWING TREATMENT LINES? 
THE ISSUE OF MAINTENANCE AND 
TREATMENT BEYOND PROGRESSION
The choice of  an upfront bevacizumab-based combi-
nation is considered a widely accepted standard treat-
ment option for the majority of  advanced CRC patients. 
Although supported by limited evidence, to continue 
the angiogenic inhibitor until disease progression is not 
uncommon in the clinical practice, especially for those 
patients who partially or entirely withhold the associated 
chemotherapy because of  toxicity or towering cumulative 
doses of  oxaliplatin[59]. Actually, results of  randomized 
trials such as MACRO[60], DREAM[61], and COIN-B[62] 
suggest to continue bevacizumab as maintenance therapy 
until disease progression. In the MACRO trial, 480 CRC 
patients were randomly assigned to receive six cycles of  
bevacizumab, capecitabine, and oxaliplatin followed by 
bevacizumab either alone or combined with the same 
chemotherapy regimen until progression. A slightly long-
er median PFS was reported in the combination arm (10.4 
mo vs 9.7 mo, HR = 1.1, P = 0.38), although burdened by 
a higher rate of  severe sensory neuropathy (26% vs 8%, P 
= 0.0001) and HFS (13% vs 7%, P = 0.03). The primary 
analysis of  DREAM demonstrated that a maintenance 
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therapy with bevacizumab and erlotinib may significantly 
prolong median PFS (10.2 mo vs 9.3 mo, HR = 0.76; 
95%CI: 0.61-0.94, P = 0.009) but not median OS (28.5 
mo vs 27.0 mo, HR = 0.89; 95%CI: 0.7-1.12, P = 0.31) 
after a first-line bevacizumab-based induction therapy[63]. 
The additive value of  erlotinib to bevacizumab in this 
setting is however unconfirmed[64]. Yet, the issue regard-
ing the role of  bevacizumab in the maintenance phase 
was not formally addressed until recently. SAKK 41/06[65] 
and CAIRO-3[66] phase Ⅲ trials compared observation to 
a maintenance strategy following an induction phase of  
chemotherapy plus bevacizumab. In the non-inferiority 
Swiss study, 262 CRC patients without disease progres-
sion at 4-6 mo since treatment start were randomized 
to continue on single-agent bevacizumab until disease 
progression or observation. Even though median PFS (+ 
1.2 mo) and OS (+ 3.3 mo) were both longer for patients 
who continued on bevacizumab, the trial formally failed 
to meet its primary endpoint, since the median time to 
progression did not differ sufficiently between treatment 
arms (17.9 wk vs 12.6 wk; HR = 0.74; 95%CI: 0.57-0.94, 
P = 0.47; with a non-inferiority limit for HR = 0.727). In 
CAIRO-3 trial, patients without disease progression after 
6 cycles of  capecitabine, oxaliplatin (CAPOX regimen) 
and bevacizumab were randomized to observation or 
continuing with capecitabine and bevacizumab. Upon the 
first disease progression, CAPOX plus bevacizumab was 
reintroduced and maintained until the second evidence 
of  progression. The primary endpoint was the PFS2, 
defined as the time from randomization to progression 
upon treatment re-introduction. Patients in the mainte-
nance arm achieved a significantly longer PFS2 (11.8 mo 
vs 10.5 mo, HR = 0.81; 95%CI: 0.67-0.98, P = 0.028), 
PFS (8.5 mo vs 4.1 mo, HR = 0.44; 95%CI: 0.36-0.53, P 
< 0.00001) and a non-significant advantage in OS (21.7 
mo vs 18.2 mo, HR = 0.87; 95%CI: 0.71-1.06, P = 0.156), 
that became significant in the adjusted analysis (HR = 
0.80). AIO KRK0207, a phase Ⅲ randomized trial com-
paring observation to maintenance with either bevacizu-
mab alone or bevacizumab plus capecitabine, will clarify 
if  a maintenance treatment, instead of  a full holiday 
period, is actually needed for all patients. In conclusion, 
while reasonable, safe, and clinically feasible, whether a 
maintenance therapy is needed for all patients is still an 
open question. 
The role of  cetuximab in the maintenance therapy is 
also being investigated. The two-arm phase Ⅱ COIN-B 
study randomized 169 patients with unresectable KRAS 
wild-type CRC to intermittent chemotherapy plus con-
tinuous or intermittent cetuximab as first-line treatment. 
Continuous cetuximab was associated with a longer 
failure free survival (FFS), chemotherapy-free interval 
(3.7 mo vs 5.1 mo) and time to progression (20.1 mo 
vs 18.4 mo). Median FFS was 12.0 and 13.7 mo, re-
spectively[62]. The phase Ⅲ Macbeth trial (EUDRACT 
2011-000840-70) is an ongoing multicenter, randomized, 
open-label study designed to evaluate the efficacy and 
safety of  eight cycles of  FOLFOXIRI plus cetuximab 
followed by maintenance with cetuximab or bevacizumab 
as first-line treatment for unresectable KRAS wild-type 
metastatic CRC patients. 
Another point of  discussion is the use of  antiang-
iogenics beyond disease progression. Data from retro-
spective registries such as BRITE[67] or ARIES[68] suggest-
ed a survival benefit with the use of  bevacizumab beyond 
disease progression. More recently, the randomized phase 
Ⅲ ML18147 trial prospectively tested the efficacy of  
maintaining bevacizumab beyond disease progression[69]. 
After the failure of  a bevacizumab-containing first-line 
treatment, 820 patients were randomized to receive a dif-
ferent second-line chemotherapy with or without bevaci-
zumab. Those that continued on the antiangiogenic agent 
reported significantly longer OS (11.2 mo vs 9.8 mo; HR 
= 0.81; 95%CI: 0.69-0.94, P = 0.0062) and PFS (5.7 mo 
vs 4.1 mo, HR = 0.68; 95%CI: 0.59-0.78, P < 0.0001). 
Toxicity profiles were similar between the two arms, al-
though more bleedings (2% vs 1%), venous thromboem-
bolic events (5% vs 3%), and gastrointestinal perforations 
(2% vs < 1%) were noted among those receiving bevaci-
zumab. In the phase Ⅲ BEBYP trial[70], 184 patients who 
had failed a bevacizumab-based first-line treatment were 
randomized to receive second-line chemotherapy with 
or without bevacizumab. The trial was stopped early, as 
soon as the positive results of  the ML18147 were dif-
fused. Performance status (ECOG PS 0 vs 1-2), length of  
the chemotherapy-free interval (< or > 3 mo), and type 
of  second-line chemotherapy were considered as stratifi-
cation factors. Two thirds of  the patients received oxali-
platin-based combinations in both treatment arms. After 
a median follow-up of  22 mo, the results confirmed 
the benefit in PFS (6.8 mo vs 5 mo, HR = 0.72; 95%CI: 
0.54-0.97, P = 0.029) for those maintained on bevacizu-
mab, while OS data are still immature to be analyzed.
Indirect evidence supports how CRC patients may 
benefit from further angiogenic treatments after dis-
ease progression while on bevacizumab. The phase Ⅲ 
VELOUR trial showed the efficacy of  aflibercept (a fu-
sion protein with high affinity to all VEGF-A isoforms, 
VEGF-B, PlGF-1, and PIGF-2) in combination with 
FOLFIRI in 1,266 CRC patients who had failed a first-
line oxaliplatin-based therapy[71]. Both median OS (13.5 
mo vs 12.06 mo, HR = 0.817; 95%CI: 0.71-0.94, P = 
0.0032) and PFS (6.9 mo vs 4.67 mo, HR = 0.76) were 
significantly longer in those who received FOLFIRI 
and aflibercept. Importantly, prior exposition to antian-
giogenics did not reduced the outcome effect. Actually, 
a similar benefit in PFS (6.7 mo vs 3.9 mo, HR = 0.66; 
95%CI: 0.51-0.85) and OS (12.5 mo vs 11.7 mo, HR = 
0.86; 95%CI: 0.67-1.10) was reported for the use of  af-
libercept in those who had received bevacizumab as part 
of  their upfront treatment (approximately 28% in both 
treatment arms). Regorafenib is another agent with broad 
antiangiogenic properties[72]. In the CORRECT trial, 
760 chemorefractory CRC patients were randomized 2:1 
to regorafenib (160 mg daily in a 3-wk-on, 1-week-off  
schedule) or placebo[73]. All patients had previously re-
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ceived bevacizumab. Median OS was 6.4 mo in the rego-
rafenib group vs 5.0 mo in the placebo group (HR = 0.77; 
95%CI: 0.64-0.94).
Large, international efforts have tried to define who 
are the patients more likely to benefit from the antian-
giogenic strategy. Unfortunately, given the complexity of  
cancer-related angiogenesis, conflicting results have been 
reported both at molecular[74] or clinical levels[75,76]. The 
prospective validation of  other single predictive biomark-
ers such as baseline LDH value[75], number of  circulating 
endothelial cells[77], or level of  miRNA[78] are still pending, 
but will unlikely succeed. 
WILL THE FIRST-LINE CHOICE IMPACT 
ON FOLLOWING TREATMENT LINES?
If  and how the first-line therapy may influence further 
treatment is a matter of  debate at many levels (molecular, 
clinical, regulatory). Nevertheless, how oncologists de-
cide the sequence of  treatment to use should be always 
based on a solid mainstay. The following reasoning is 
founded on a critical analysis of  major phase Ⅲ random-
ized studies.
Accordingly to the results of  a pivotal phase Ⅲ trial 
that compared FOLFOX6 followed by FOLFIRI to 
FOLFIRI followed by FOLFOX6 and showed similar 
outcomes regardless of  the treatment sequence[79], the 
backbone treatment used after first disease progression 
of  disease is currently based on a crossover from an iri-
notecan- to an oxaliplatin-based regimen or vice-versa. In 
that trial, 220 patients were randomized to receive initially 
either FOLFIRI or FOLFOX6 and to switch to the other 
regimen at disease progression. Neither first-line RR (56% 
vs 54%), nor first-line median PFS (8.5 mo vs 8 mo, P 
= 0.26), nor median OS (21.5 mo vs 20.6 mo, P = 0.99) 
were statistically different between treatment arms.
Ten years after the widespread use of  biologics has 
begun in the clinical practice, the scenario has become 
much more complicated, particularly in patients with 
KRAS wild-type tumors that may benefit from a scope 
of  different treatments. The initial choice of  the upfront 
chemotherapy regimen, however, retains its value.
When opting for an irinotecan-based first-line regi-
men, either bevacizumab[80] or cetuximab[81,82] could be 
used as optimal biologic partners. Either way the patient 
is started, survival results of  the ECOG E3200 phase 
Ⅲ trial[83] would suggest to use FOLFOX plus beva-
cizumab as second-line treatment after an irinotecan-
based first-line failure. Later on, following on the 
treatment route, the choice of  third-line may become 
critical. In this setting, while strong data support the 
use of  EGFR-inhibitors either alone[84,58] or combined 
to irinotecan[85],evidence suggesting potential benefit 
from retreating patients with EGFR-inhibitors is more 
shaggy[86,87] or under investigation[88]. Regorafenib, indeed, 
would be an appropriate choice for all highly pretreated 
patients[73]. Consequently, the treatment algorithm would 
offer 4 potential lines of  treatment if  the patient receive 
upfront an irinotecan-based chemotherapy plus beva-
cizumab, but one treatment line would be lost if  the 
patient starts with an irinotecan-based therapy plus ce-
tuximab. This hypothetical reasoning may be revised (and 
even reversed) if  the outcome results of  CALGB 80405 
trial will confirm the unexpected 3.7-mo median survival 
advantage reported in FIRE-3 for KRAS wild-type CRC 
patients receiving FOLFIRI and cetuximab in first-line. 
When opting for a first-line treatment including oxali-
platin, antiangiogenic drugs[60,89] or EGFR-inhibitor[90,91] 
may be used in combination, although the upfront use of  
bevacizumab seems to be preferable because it may bet-
ter fit in the maintenance strategy[92,93] for its convenience 
and safety when combined to capecitabine[94]. Moreover, 
the upfront combination of  oxaliplatin with an EGFR-
inhibitor requires more detailed molecular biology data 
(see paragraph 4) and increased watchfulness if  using an 
oral fluoropyrimidine[91]. At disease progression, many 
reasons strongly support the choice of  switching to an 
irinotecan-based regimen, including the potential cumu-
lative neurotoxicity of  prolonged oxaliplatin use. Since 
in second-line setting many alternative options exist, to 
establish which is the optimal biologic to be delivered is 
challenging and depends on the previous use of  targeted 
agents. A number of  second-line randomized trials have 
investigated the role of  biological agents in the treat-
ment of  CRC patients not previously exposed to EGFR-
inhibitors. Tested agents included bevacizumab[69], af-
libercept[71], cetuximab[95], or panitumumab[96,97]. Of  note, 
in all those trials patients may have been upfront treated 
with bevacizumab, but the proportion of  those who did 
receive the angiogenic inhibitors in first-line vastly varied, 
ranging from 2%[97] to 100%[69]. Results of  ML18147 and 
VELOUR have been already discussed (see before). In 
the phase Ⅲ EPIC study[92], 1298 patients who had prior 
failed a first-line oxaliplatin-based regimen, were random-
ized to receive irinotecan plus cetuximab or irinotecan 
alone. The addition of  cetuximab to irinotecan resulted 
in a significant improvement of  PFS (4.0 mo vs 2.6 mo, 
HR = 0.69; 95%CI: 0.617-0.776, P < 0.0001), but no OS 
advantage was reported (10.7 mo vs 10.0 mo, HR = 0.97). 
Panitumumab was tested in another randomized phase 
Ⅲ trial, comparing in 1,186 pretreated metastatic CRC 
patients, the addition of  panitumumab itself  to FOL-
FIRI, to placebo. A significant improvement in PFS was 
observed (5.9 mo vs 3.9 mo, HR = 0.73; 95%CI: 0.59-0.90, 
P = 0.004), with a trend for longer OS (14.5 mo vs 12.5 
mo, HR = 0.85; 95%CI: 0.70-1.04, P = 0.12). Similarly, 
the PICCOLO study[97] reported higher RR (34% vs 12%, 
P < 0.001), longer PFS (HR = 0.78; 95%CI: 0.64-0.95, P 
= 0.015), but no survival advantage (10.9 mo vs 10.4 mo; 
HR = 1.01; 95%CI: 0.83-1.23, P = 0.91) for the use of  
panitumumab and irinotecan-based chemotherapy com-
pared to irinotecan alone. If  the upfront biologic was the 
EGFR-inhibitor, less options are permitted (see point A). 
Again, regorafenib may be considered as salvage treat-
ment for all pretreated patients. As discussed before, if  
the patient is started with a EGFR-inhibitor, the number 
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of  therapeutic options seems narrowed.
CHOOSING A FIRST-LINE TREATMENT 
FOR CRC PATIENTS WHO HAVE FAILED 
ADJUVANT OXALIPLATIN - IS THERE 
ANY DIFFERENCE? 
Since approximately 50% of  stage Ⅲ and 20% of  stage 
Ⅱ CRC patients do eventually recur, one third of  patients 
present with metachronous metastatic disease, which is 
currently defined as more than 1 year between the occur-
rence of  the primitive tumor and metastasis. Not surpris-
ingly, a significant proportion of  those patients may have 
already received an oxaliplatin-based chemotherapy, a 
universally confirmed standard regimen in the adjuvant 
setting[98-100]. Indeed, patients enrolled in first-line phase 
Ⅲ randomized trials which had already been exposed to 
adjuvant chemotherapy ranged from 8% to 32% (Table 
1). However, having received a previous treatment with 
oxaliplatin was sometimes included among the exclusion 
criteria, and even when it was permitted, how many of  
those pretreated patients had actually received an oxalipl-
atin-based regimen was rarely specified in the publication.
To fully understand the importance of  this point, 
some data should be further discussed. The analysis of  
over 20000 CRC patients included in the ACCENT da-
tabase showed that the risk of  recurrence peaks between 
18 and 24 mo after radical surgery, and then decreases 
over time[101]. Most patients who recur, therefore, develop 
metastatic disease within 18 mo since the end of  postop-
erative chemotherapy.
The use of  oxaliplatin is burdened by the frequent oc-
currence of  chronic peripheral sensory neuropathy[102,103], 
a dose-dependent disturbing toxicity characterized by 
dysesthesia and distal paresthesia, that often negatively 
impacts on patients’ quality of  life[104]. In addition, acute 
neuropathy (oral-facial and peripheral), which in some 
cases is induced or exacerbated by exposure to cold, was 
also reported. This neurological side-effect, quite unusual 
in the initial chemotherapy cycles, frequently appears dur-
ing the treatment course as long as the cumulative dose 
of  oxaliplatin increases.
The vast majority of  the patients enrolled in random-
ized clinical trials that tested oxaliplatin in the adjuvant 
setting developed peripheral sensory neuropathy. In 
MOSAIC trial, any grade peripheral neurotoxicity was 
observed in 92% of  patients, while grade 2 (moderate) 
or grade 3 (severe) was reported in 44%. Often, howev-
er, the symptoms ameliorated or resolved over time: one 
and four years after treatment, 30% and 15% of  patients 
had minimal residual toxicity, respectively. In NSABP 
C-07 trial, grade 3-4 peripheral neuropathy was reported 
in 8.4% of  patients. At 1 year from random assignment, 
the rate of  severe neurotoxicity was 0.6%. The inferior 
rate of  neurotoxicity may be due to the lower cumulative 
dose of  oxaliplatin in NSABP C-07 (9 planned doses of  
85 mg/m2) compared to MOSAIC (12 planned doses of  
85 mg/m2).
In NO16968 study, any grade peripheral neuropathy 
occurred in 78% of  patients exposed to oxaliplatin, and 
grade 3-4 in 11%. At the end of  adjuvant treatment, re-
sidual neurotoxicity was still present in 68% of  patients.
Toxicity data were confirmed in another randomized 
trial that tested the efficacy of  bevacizumab combined to 
oxaliplatin-based chemotherapy in the adjuvant setting[105]. 
Grade 2 or grade 3 sensory neuropathy was reported in 
43.7% of  patients treated with FOLFOX6 and in 48.9 % 
of  those treated with FOLFOX6 + bevacizumab, with the 
delivery of  similar median doses of  oxaliplatin. Notably, 
about 10%-20% of  patients developed severe neurotoxic-
ity after cumulative oxaliplatin dose of  750-850 mg/m2[106].
Recently, a number of  studies reported on a long-
lasting oxaliplatin-induced peripheral neurotoxicity[107,108]. 
Those studies showed that a not-negligible proportion of  
patients (5%-15%) still suffer from chronic neurotoxicity 
many years after treatment end, and refer troublesome 
numbness or tingling of  hands and feet. Than, it is con-
ceivable that a proportion of  oxaliplatin-exposed patients 
may still have neurological symptoms at the time of  
recurrence. In order to prevent or reduce the incidence 
and intensity of  this toxicity in the adjuvant setting, 
several strategies are being studied, including a reduced 
exposition to oxaliplatin[109] or the potential use of  neu-
roprotectants such as glutathione[110], oxcarbazepine[111], 
or venlafaxine[112], but no preventive treatment has been 
recognized as a standard. Moreover, retrospective stud-
ies suggested that the iv supplementation with calcium 
and magnesium may be useful[113]. However, a random-
ized phase Ⅲ trial enrolling 362 radically resected CRC 
patients with no pre-existing peripheral neuropathy to 
compare calcium/magnesium supplementation vs placebo 
failed to show any significant difference among treatment 
arms in the rate of  moderate or severe neuropathy[114].
For all these reasons, whether the clinical outcome 
of  an oxaliplatin-based first-line therapy is maintained 
in patients who had been already exposed to the drug in 
the adjuvant setting is unclear and few data are available 
on this regard. Recently, a retrospective study assessed 
the first-line RR to either FOLFIRI or FOLFOX in 32 
patients with advanced CRC who had previously received 
adjuvant FOLFOX after radical surgery[115]. The median 
time between the beginning of  adjuvant chemotherapy 
and disease recurrence was 1.7 years. The overall RR was 
17% in the FOLFOX group vs 36% in the FOLFIRI 
group. Despite a trend in favor of  FOLFIRI, the differ-
ence was not statistically significant (P = 0.22). 
For patients with residual neurotoxicity at the time 
of  disease recurrence, the stop-and-go strategy may be 
an appropriate option to avoid the side-effect worsen-
ing while still using an active agent. Two different ran-
domized trials showed a clinically significant reduction 
in the rate of  severe neurotoxicity with the use of  this 
strategy[116,117]. In conclusion, an oxaliplatin-based regi-
men could still be an option for patients without or with 
minimal residual neurotoxicity that become metastatic 
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after at least 12 mo since the end of  an oxaliplatin-based 
adjuvant therapy. Oppositely, for those who relapse early 
(within 12 mo) or still have clinically significant neurotox-
icity, it is reasonable to choose a regimen without oxali-
platin and delay as much as possible the reintroduction 
of  the neurotoxic drug. 
CONCLUSION
The landscape of  CRC treatment is changing very fast, 
and the availability of  new therapeutic options has creat-
ed new challenges and generated more complicated treat-
ment algorithms. In conclusion, we would like to suggest 
the reader short possible answers to the initial questions. 
Undoubtedly, the optimal choice of  the first-line treat-
ment is still of  great importance. When considering this 
choice, patients’ performance status, comorbidities and 
desires should be considered as well as the ultimate goal 
of  the treatment and the molecular features of  the tu-
mor. An highly intensive regimen is particularly indicated 
for younger patients without comorbid conditions or 
for those patients with aggressive colorectal carcinomas 
(symptomatic, bulky disease or BRAF mutant tumors). 
The application of  a deeper molecular analysis not only 
helps identifying those patients who may benefit the most 
from EGFR-inhibitors but also has a prognostic value. 
In the majority of  cases with RAS and BRAF wild-type 
status, a first-line combination with an EGFR-inhibitor 
seems to be the preferred treatment option, while the 
antiangiogenic strategy should be pursued in those with 
RAS mutated tumors or when a less aggressive treatment 
is favoured. The exposition to oxaliplatin in the adjuvant 
setting may somehow limit its use in the advanced phases 
of  the disease due to possible cumulative neurotoxicity. 
Randomized trials, however, are verifying if  a shorter 
oxaliplatin-based adjuvant treatment may be equally pro-
tecting and less toxic. Notably, many other new molecules 
are being studied in randomized trials and, hopefully, re-
sults of  those studies will help clinicians further refining 
the current treatment paradigms.
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